Zeposia compared with placebo was more effective as an induction and maintenance therapy in patients with moderately to severely active ulcerative colitis, according to a study published in The New England Journal of Medicine.

“The results of this phase 3 trial showed that a once-daily oral formulation of ozanimod, a SIP receptor modulator, provided clinical efficacy in patients with moderately to severely active ulcerative colitis,” William J. Sandborn, MD, of the division of gastroenterology at the University of California, San Diego, and colleagues wrote. “Treatment with

Full Article: https://www.healio.com/news/gastroenterology/20210929/zeposia-efficacious-as-induction-maintenance-therapy-for-ulcerative-colitis